Viatris Inc (VTRS)

$8.98 +0.04 (0.45%)
Market Cap 10.49B
Revenue (ttm) 14.74B
Net Income (ttm) -634.20M
EPS (ttm) N/A
PE Ratio 3.52
Forward PE 3.89
Profit Margin -4.30%
Debt to Equity Ratio 1.02
Volume 7,163,600
Avg Vol 11,852,400
Day's Range N/A - N/A
Shares Out 1.17B
Stochastic %K 45%
Beta 0.90
Analysts Sell
Price Target $11.18

Company Profile

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 724 514 1800
Address:
Robert J. Coury Global Center, 1000 Mylan Boulevard, Canonsburg, United States
scientificway
scientificway Aug. 5 at 4:18 AM
$VTRS check out MDXG, huge rev, eps, guidance up. , check it out, anyone there?
1 · Reply
ZacksResearch
ZacksResearch Aug. 4 at 6:21 PM
Can $VTRS turn around after losing 29% in a year? 📉 Growth in brands like Creon and Brufen within Developed Markets may boost sales, but North America sales face challenges due to plant inspections in India and expected generic competition. Developed Markets revenue is pegged at $2.1B, but mixed earnings history clouds the forecast. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2663504/viatris-poised-to-report-q2-earnings-whats-in-store-for-the-stock?cid=sm-stocktwits-2-2663504-body-5867&ADID=SYND_STOCKTWITS_TWEET_2_2663504_BODY_5867
0 · Reply
ZacksResearch
ZacksResearch Aug. 4 at 5:09 PM
$VTRS earnings on deck — can international growth offset U.S. pressure? Branded drug sales in Europe and China are climbing, helping cushion generic weakness in North America. Full preview here 👉 https://www.zacks.com/stock/news/2663504/viatris-poised-to-report-q2-earnings-whats-in-store-for-the-stock?cid=sm-stocktwits-2-2663504-teaser-5812&ADID=SYND_STOCKTWITS_TWEET_2_2663504_TEASER_5812
0 · Reply
fibonacci6180
fibonacci6180 Aug. 2 at 12:22 AM
$VTRS Trading idea - Entry point > 8.8/61.80% Chart time frame:B A) 15 min(1W-3M) B) 1 hr(3M-6M) C) 4 hr(6M-1year) D) 1 day(1-3years) Stock progress:A A) Keep rising over 61.80% resistance B) 61.80% resistance C) 61.80% support D) Hit the bottom E) Hit the top
0 · Reply
zzzdoc
zzzdoc Aug. 1 at 12:51 AM
$VTRS ChatGPT: what are the 17 pharmas trump sent a letter to? President Trump sent letters to 17 pharmaceutical companies demanding they lower drug prices to match the lowest rates offered in other developed nations. The companies named were: AbbVie Amgen AstraZeneca Boehringer Ingelheim Bristol Myers Squibb Eli Lilly EMD Serono Genentech Gilead GSK (GlaxoSmithKline) Johnson & Johnson Merck Novartis Novo Nordisk Pfizer Regeneron Sanofi The letters outlined expectations for pricing reforms, including offering “most-favored-nation” prices to Medicaid patients and cutting out middlemen to sell directly to consumers at competitive rates. If they don’t comply, the administration warned it would use “every tool in our arsenal” to protect American families from high drug costs. Shorts, this will not last long
0 · Reply
ItsCarRamRod
ItsCarRamRod Jul. 31 at 6:17 PM
$VTRS I love it, couldn't happen to a better company.
1 · Reply
ItsCarRamRod
ItsCarRamRod Jul. 30 at 7:25 PM
$VTRS who knew VTRS was so rate sensitive.
0 · Reply
ExoticExpansion
ExoticExpansion Jul. 29 at 2:55 PM
$VTRS whatever the ceo is doing he does not deserve 15m salary. Hes a horrible ceo with no results.
1 · Reply
dllydalley29
dllydalley29 Jul. 25 at 1:47 PM
$VTRS Resistance here. Can we finally punch through to 10?
2 · Reply
ZacksResearch
ZacksResearch Jul. 21 at 6:12 PM
$VTRS tumbles 4.21% after late-stage study failure — what’s next? 📉 Viatris’ MR-139 ophthalmic ointment didn’t meet its primary endpoint in a phase III study for blepharitis, adding pressure to a share price already down 26.8% YTD. 😬 Full details on VTRS’ portfolio and next steps here 👉 https://www.zacks.com/stock/news/2599617/vtrs-down-on-late-stage-study-failure-of-eye-disease-drug?cid=sm-stocktwits-2-2599617-body-2758&ADID=SYND_STOCKTWITS_TWEET_2_2599617_BODY_2758
0 · Reply
Latest News on VTRS
Viatris Announces Quarterly Dividend

Aug 5, 2025, 6:59 AM EDT - 20 hours ago

Viatris Announces Quarterly Dividend

Viatris Announces Appointment of David Simmons to the Company's Board of Directors

Aug 5, 2025, 6:55 AM EDT - 20 hours ago

Viatris Announces Appointment of David Simmons to the Company's Board of Directors

Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference

Aug 1, 2025, 10:00 AM EDT - 4 days ago

Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference

10 dividend stocks with yields up to 6.92% and plenty of cash flow for higher payouts

Jul 22, 2025, 11:19 AM EDT - 14 days ago

10 dividend stocks with yields up to 6.92% and plenty of cash flow for higher payouts

CIVI CMCSA CRGY CWEN KSS LNC NXST

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review

Jul 18, 2025, 2:17 PM EDT - 18 days ago

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review

Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target

Jul 18, 2025, 8:47 AM EDT - 18 days ago

Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target

Viatris eye therapy fails to meet late-stage trial goal

Jul 18, 2025, 7:07 AM EDT - 18 days ago

Viatris eye therapy fails to meet late-stage trial goal

Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis

Jul 18, 2025, 6:59 AM EDT - 18 days ago

Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis

Viatris: A Contrarian Bet With Virtually No Downside

Jul 16, 2025, 3:19 AM EDT - 21 days ago

Viatris: A Contrarian Bet With Virtually No Downside

Dogs Of The S&P 500: 14 Ideal 'Safer' July Dividend Buys

Jul 11, 2025, 5:23 PM EDT - 25 days ago

Dogs Of The S&P 500: 14 Ideal 'Safer' July Dividend Buys

AES AMCR ARE BMY CAG CPB CVX

Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia

Jun 26, 2025, 6:55 AM EDT - 5 weeks ago

Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia

Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025

Jun 12, 2025, 4:30 PM EDT - 7 weeks ago

Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025

Viatris Inc. (VTRS) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Jun 9, 2025, 1:06 PM EDT - 2 months ago

Viatris Inc. (VTRS) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Viatris Inc. (VTRS) Presents at Jefferies Global Healthcare Conference Transcript

Jun 5, 2025, 11:04 AM EDT - 2 months ago

Viatris Inc. (VTRS) Presents at Jefferies Global Healthcare Conference Transcript

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris

Jun 2, 2025, 1:12 PM EDT - 2 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris

Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Jun 2, 2025, 8:00 AM EDT - 2 months ago

Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris

May 31, 2025, 8:45 AM EDT - 2 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris

VTRS CLASS NOTICE: Viatris Inc. Investors may have been Affected by Fraud – Contact BFA Law before June 3 Court Deadline (NASDAQ:VTRS)

May 31, 2025, 7:07 AM EDT - 2 months ago

VTRS CLASS NOTICE: Viatris Inc. Investors may have been Affected by Fraud – Contact BFA Law before June 3 Court Deadline (NASDAQ:VTRS)

SHAREHOLDER REMINDER: Berger Montague Reminds Viatris (NASDAQ: VTRS) Investors of the June 3, 2025 Deadline

May 30, 2025, 9:06 AM EDT - 2 months ago

SHAREHOLDER REMINDER: Berger Montague Reminds Viatris (NASDAQ: VTRS) Investors of the June 3, 2025 Deadline

DEADLINE NEXT WEEK: Berger Montague Advises Viatris (NASDAQ: VTRS) Investors to Contact the Firm Before June 3, 2025

May 27, 2025, 10:38 AM EDT - 2 months ago

DEADLINE NEXT WEEK: Berger Montague Advises Viatris (NASDAQ: VTRS) Investors to Contact the Firm Before June 3, 2025

VTRS FRAUD: Suffer Losses on Viatris Inc.? You may have been Affected by Fraud and are Urged to Contact BFA Law (NASDAQ:VTRS)

May 25, 2025, 7:42 AM EDT - 2 months ago

VTRS FRAUD: Suffer Losses on Viatris Inc.? You may have been Affected by Fraud and are Urged to Contact BFA Law (NASDAQ:VTRS)

VTRS FRAUD NEWS: Viatris Inc. is Being Sued for Securities Fraud; Investors That Lost Money Are Urged to Contact BFA Law by June 3 Court Deadline

May 23, 2025, 3:18 PM EDT - 2 months ago

VTRS FRAUD NEWS: Viatris Inc. is Being Sued for Securities Fraud; Investors That Lost Money Are Urged to Contact BFA Law by June 3 Court Deadline

Viatris to Participate in Upcoming Investor Conferences

May 22, 2025, 6:59 AM EDT - 2 months ago

Viatris to Participate in Upcoming Investor Conferences

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Viatris Lawsuit – VTRS

May 21, 2025, 1:18 PM EDT - 2 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Viatris Lawsuit – VTRS

VTRS LAWSUIT: Lose Money on Viatris Inc.? Contact BFA Law before June 3 Court Deadline

May 21, 2025, 8:46 AM EDT - 2 months ago

VTRS LAWSUIT: Lose Money on Viatris Inc.? Contact BFA Law before June 3 Court Deadline

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris

May 14, 2025, 2:02 PM EDT - 2 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris

Viatris Inc. (VTRS) BofA Securities 2025 Healthcare Conference (Transcript)

May 14, 2025, 1:59 PM EDT - 2 months ago

Viatris Inc. (VTRS) BofA Securities 2025 Healthcare Conference (Transcript)

scientificway
scientificway Aug. 5 at 4:18 AM
$VTRS check out MDXG, huge rev, eps, guidance up. , check it out, anyone there?
1 · Reply
ZacksResearch
ZacksResearch Aug. 4 at 6:21 PM
Can $VTRS turn around after losing 29% in a year? 📉 Growth in brands like Creon and Brufen within Developed Markets may boost sales, but North America sales face challenges due to plant inspections in India and expected generic competition. Developed Markets revenue is pegged at $2.1B, but mixed earnings history clouds the forecast. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2663504/viatris-poised-to-report-q2-earnings-whats-in-store-for-the-stock?cid=sm-stocktwits-2-2663504-body-5867&ADID=SYND_STOCKTWITS_TWEET_2_2663504_BODY_5867
0 · Reply
ZacksResearch
ZacksResearch Aug. 4 at 5:09 PM
$VTRS earnings on deck — can international growth offset U.S. pressure? Branded drug sales in Europe and China are climbing, helping cushion generic weakness in North America. Full preview here 👉 https://www.zacks.com/stock/news/2663504/viatris-poised-to-report-q2-earnings-whats-in-store-for-the-stock?cid=sm-stocktwits-2-2663504-teaser-5812&ADID=SYND_STOCKTWITS_TWEET_2_2663504_TEASER_5812
0 · Reply
fibonacci6180
fibonacci6180 Aug. 2 at 12:22 AM
$VTRS Trading idea - Entry point > 8.8/61.80% Chart time frame:B A) 15 min(1W-3M) B) 1 hr(3M-6M) C) 4 hr(6M-1year) D) 1 day(1-3years) Stock progress:A A) Keep rising over 61.80% resistance B) 61.80% resistance C) 61.80% support D) Hit the bottom E) Hit the top
0 · Reply
zzzdoc
zzzdoc Aug. 1 at 12:51 AM
$VTRS ChatGPT: what are the 17 pharmas trump sent a letter to? President Trump sent letters to 17 pharmaceutical companies demanding they lower drug prices to match the lowest rates offered in other developed nations. The companies named were: AbbVie Amgen AstraZeneca Boehringer Ingelheim Bristol Myers Squibb Eli Lilly EMD Serono Genentech Gilead GSK (GlaxoSmithKline) Johnson & Johnson Merck Novartis Novo Nordisk Pfizer Regeneron Sanofi The letters outlined expectations for pricing reforms, including offering “most-favored-nation” prices to Medicaid patients and cutting out middlemen to sell directly to consumers at competitive rates. If they don’t comply, the administration warned it would use “every tool in our arsenal” to protect American families from high drug costs. Shorts, this will not last long
0 · Reply
ItsCarRamRod
ItsCarRamRod Jul. 31 at 6:17 PM
$VTRS I love it, couldn't happen to a better company.
1 · Reply
ItsCarRamRod
ItsCarRamRod Jul. 30 at 7:25 PM
$VTRS who knew VTRS was so rate sensitive.
0 · Reply
ExoticExpansion
ExoticExpansion Jul. 29 at 2:55 PM
$VTRS whatever the ceo is doing he does not deserve 15m salary. Hes a horrible ceo with no results.
1 · Reply
dllydalley29
dllydalley29 Jul. 25 at 1:47 PM
$VTRS Resistance here. Can we finally punch through to 10?
2 · Reply
ZacksResearch
ZacksResearch Jul. 21 at 6:12 PM
$VTRS tumbles 4.21% after late-stage study failure — what’s next? 📉 Viatris’ MR-139 ophthalmic ointment didn’t meet its primary endpoint in a phase III study for blepharitis, adding pressure to a share price already down 26.8% YTD. 😬 Full details on VTRS’ portfolio and next steps here 👉 https://www.zacks.com/stock/news/2599617/vtrs-down-on-late-stage-study-failure-of-eye-disease-drug?cid=sm-stocktwits-2-2599617-body-2758&ADID=SYND_STOCKTWITS_TWEET_2_2599617_BODY_2758
0 · Reply
ZacksResearch
ZacksResearch Jul. 21 at 12:50 PM
$VTRS just took another hit — here’s why the selloff matters 👀 The stock dropped after its phase III trial for eye drug MR-139 failed, piling onto an already weak performance. Full breakdown here 👉 https://www.zacks.com/stock/news/2599617/vtrs-down-on-late-stage-study-failure-of-eye-disease-drug?cid=sm-stocktwits-2-2599617-teaser-2755&ADID=SYND_STOCKTWITS_TWEET_2_2599617_TEASER_2755
0 · Reply
dllydalley29
dllydalley29 Jul. 18 at 4:09 PM
$VTRS Go ahead...make my day.
1 · Reply
OpenOutcrier
OpenOutcrier Jul. 18 at 11:59 AM
$VTRS (-3.7% pre) Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis https://ooc.bz/l/70414
0 · Reply
G101SPM
G101SPM Jul. 18 at 11:24 AM
$VTRS $8.95 bid. SELL/TAKE EVEN on limited SPM tag improvement. DAC (dollar average cost) $8.70 (5.8.25).
0 · Reply
DonCorleone77
DonCorleone77 Jul. 18 at 11:02 AM
$VTRS Viatris announces pimecrolimus trial did not meet primary endpoint
2 · Reply
ItsCarRamRod
ItsCarRamRod Jul. 11 at 3:11 PM
$VTRS crashing just as expected.
1 · Reply
lecorb
lecorb Jul. 9 at 11:20 AM
$VTRS $JNJ $TEVA J&J wins appeals court ruling against Teva and Viatris in patent dispute over neuro drug https://seekingalpha.com/news/4466089-jj-wins-appeals-court-ruling-against-teva-viatris?mailingid=40610743&messageid=2900&serial=40610743.17857&source=email_2900&utm_campaign=rta-stock-news&utm_content=link-3&utm_medium=email&utm_source=seeking_alpha&utm_term=40610743.17857
0 · Reply
dllydalley29
dllydalley29 Jul. 2 at 6:48 PM
$VTRS Value stocks catching a bid. Ready for double digits here. Good luck longs.
1 · Reply
StockMarketMoodToday
StockMarketMoodToday Jul. 2 at 3:40 PM
$VTRS still in strategy 2 portfolio since April 24
0 · Reply
11thestate
11thestate Jun. 30 at 11:02 AM
$VTRS stockholders filed a claim against Viatris for allegedly hiding the severity of an FDA warning tied to its Indore manufacturing plant in India. You can join this case to be notified about any new information: https://11th.com/cases/viatris-investor-suit
0 · Reply
Du57mi73
Du57mi73 Jun. 28 at 8:45 AM
$VTRS Am i dumb or is now a great time to enter into a position here?
2 · Reply
DonCorleone77
DonCorleone77 Jun. 26 at 10:32 AM
$TBPH $VTRS Theravance Biopharma announces Viatris approval for Yupelri in China Theravance Biopharma (TBPH) announced that Viatris (VTRS), has secured regulatory approval from China's National Medical Products Administration for Yupelri inhalation solution, the first once-daily nebulized long-acting muscarinic antagonist approved for maintenance treatment of chronic obstructive pulmonary disease in China. This approval triggers a one-time $7.5M from Viatris to Theravance Biopharma, which is expected to be received in Q3. Theravance Biopharma is also eligible for further sales-based milestones of up to $37.5M and tiered royalties of 14% to 20% on net sales in China. Viatris is responsible for all aspects of development and commercialization of Yupelri in China.
0 · Reply